2024
Immunotherapy utilization in stage IIIA melanoma: less may be more
Frey A, Kerekes D, Khan S, Tran T, Kluger H, Clune J, Ariyan S, Sznol M, Ishizuka J, Olino K. Immunotherapy utilization in stage IIIA melanoma: less may be more. Frontiers In Oncology 2024, 14: 1336441. PMID: 38380358, PMCID: PMC10876869, DOI: 10.3389/fonc.2024.1336441.Peer-Reviewed Original ResearchStage IIIA melanomaHigh-volume centersRisk-adjusted survivalLow-volume centersImmunotherapy utilizationAdjuvant immunotherapyStage IIIATreatment of stage III melanomaAcademic centersMultivariable Cox proportional hazards regressionStage III melanomaNational Cancer DatabaseStage III diseaseFactors associated with receiptCox proportional hazards regressionCompare patient outcomesProportional hazards regressionIII melanomaImmunotherapy receiptReceiving immunotherapyIII diseaseImmunotherapy agentsOverall survivalSurvival benefitAdjuvant treatment
2022
Unmeasured factors are associated with the use of completion lymph node dissection (CLND) in melanoma
Leonard L, Beaty L, Thomas M, Quinn C, Colborn K, de Araujo T, Torphy R, Assumpção L, Olino K, Studts C, Franco S, McCarter M, Stewart C, Gleisner A. Unmeasured factors are associated with the use of completion lymph node dissection (CLND) in melanoma. Journal Of Surgical Oncology 2022, 127: 716-726. PMID: 36453464, DOI: 10.1002/jso.27153.Peer-Reviewed Original ResearchConceptsCompletion lymph node dissectionSentinel lymph nodesPositive sentinel lymph nodesLymph node dissectionNode dissectionMultivariable mixed-effects logistic regression modelGovernment-based insuranceNational Cancer DatabasePrimary tumor locationStage III melanomaEffect of patientContribution of patientMixed effects logistic regression modelsLogistic regression modelsTumor factorsOlder patientsSurvival benefitLymph nodesSurgical excisionStandard treatmentTumor locationCancer DatabasePatient variablesPatientsLower limbs